OncoSec to Present at Upcoming Healthcare and Investor Conferences CEO Punit Dhillon Will Present at BIOX, Cancer Immunotherapy and IN3 Device Conferences and Participate at Burrill and Cowen Conferences
SAN DIEGO, Sept. 20, 2012 /PRNewswire/ -- OncoSec Medical Inc. (OTCBB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumor cancers, announced that Punit Dhillon, President and CEO, will present at the following healthcare and investor conferences in upcoming weeks:
Noble Financial BioXposition (BIOX), University of Connecticut, Stamford Campus, Stamford, CT, September 24 at 4:00 PM ET
MD Becker Third Annual "Cancer Immunotherapy: A Long Awaited Reality" Conference, New York Academy of Medicine, New York, NY, October 4 at 9:15 AM ET
Investment in Innovation (IN3) Medical Device 360° Summit, Intercontinental Mark Hopkins, San Francisco, CA, October 16 at 10:30 AM PT
In addition, Mr. Dhillon will attend the exclusive Burrill & Company Biotech Meeting in Laguna Beach, CA on October 7-9 and the Cowen Group 15th Annual Therapeutics Conference in New York, NY on October 10.
Following the Noble Financial and MD Becker events, a video webcast of the presentations can be viewed on OncoSec's website at: http://oncosec.com/index.php/press-media/events-media/
About OncoSec Medical Inc.
OncoSec Medical Incorporated is a biopharmaceutical company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumor cancers. ImmunoPulse and NeoPulse therapies address an unmet medical need and represent a potential solution, for less invasive and less expensive therapies that are able to minimize detrimental effects resulting from currently available cancer treatments such as surgery, systemic chemotherapy or immunotherapy and other treatment alternatives. OncoSec's core technology is based upon its proprietary use of an electroporation platform to dramatically enhance the delivery and uptake of a locally delivered DNA-based immunocytokine (ImmunoPulse) or chemotherapeutic agent (NeoPulse). Treatment of various solid cancers using these powerful and targeted anti-cancer agents has demonstrated selective destruction of cancerous cells while sparing healthy normal tissues during early and late stage clinical trials. OncoSec's clinical programs include three Phase II clinical trials for ImmunoPulse targeting lethal skin cancers. More information is available at http://www.oncosec.com/. Additional information may also be found at OncoSec's Facebook, Twitter, and LinkedIn sites.
This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward looking statements." Forward looking statements are based on management's current preliminary expectations and are subject to risks and uncertainties which may cause our results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition and market conditions. These and additional risks and uncertainties are more fully described in OncoSec's filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward looking statements which speak only as of the date they are made. OncoSec disclaims any obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.
SOURCE OncoSec Medical Inc.